Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 390669

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 390669

North America Clinical Trials Market - Growth, Trends, and Forecasts (2022 - 2027)

PUBLISHED:
PAGES: 108 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4750
PDF & Excel (Team License: Up to 7 Users)
USD 5250
PDF & Excel (Site License)
USD 6500
PDF & Excel (Corporate License)
USD 8750

Add to Cart

The North America clinical trials market is expected to register a CAGR of 8.1% during the forecast period. The market will show rapid growth due to the demand for clinical trials in the emerging markets, high R&D expenditure of the pharmaceutical industry and the rising prevalence of diseases.

In emerging countries, there are numerous unmet needs of clinical trials for novel drugs, due to the increasing prevalence of infectious and tropical diseases in the region. The population is found to have has varied disease profile which is increasing with the span of time and this is expected to boost the clinical trials of new or rare diseases. Therefore the number of patients having a specific disease would act as a stimulus for biopharmaceutical companies to invest more in clinical trials for a disease segment.

According to the National Clinical Trials Registry (NCT), in 2020, there are approximately 11,865 active clinical trials under development across different phases for cancer indication in the United States.

The research and development (R&D) spending of pharmaceutical companies has also been steadily increasing over the past few years. This was mainly due to numerous patent expiries, and as a result of the patent expiration, there are many pharmaceutical companies that will have no other option but to develop new drugs. Therefore, the companies are spending more on R&D to accelerate the development of drugs through clinical trials, and henceforth increasing the overall market.

Key Market Trends

Phase III is the Largest Segment Under Phases that is Expected to Grow During the Forecast Period

The market is expected to be dominated by Phase III, with Phase I expected to witness the fastest growth. Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice. The Phase I trial in the market studied is also expected to grow at a steady rate, due to the increasing number of investigative new drug (IND) applications filed. The government initiatives in the North American countries for the promotion of drug discovery and continuous technological innovations are expected to propel the market growth. According to the National Clinical Trials Registry (NCT), currently there are about 309 active clinical trials under phase III development for cardiovascular diseases in the United States. Thus, owing to above factors the segment is expected to show growth in coming years.

Competitive Landscape

The North America Clinical Trials Market is fragmented competitive and consists of several major players. The major pharmaceutical companies are found making enormous investments in R&D, especially in the emerging nations, in order to gain opportunities for market growth in the major regions. The strategic partnerships among pharmaceutical companies and the CROs are expected to have a significant impact on the market's growth.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 51275

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Demand for Clinical Trials
    • 4.2.2 High R&D Expenditure of the Pharmaceutical Industry
    • 4.2.3 Rising Prevalence of Diseases
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Workforce for Clinical Research
    • 4.3.2 Stringent Regulations
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Phase
    • 5.1.1 Phase I
    • 5.1.2 Phase II
    • 5.1.3 Phase III
    • 5.1.4 Phase IV
  • 5.2 By Design
    • 5.2.1 Treatment Studies
      • 5.2.1.1 Randomized Control Trial
      • 5.2.1.1.1 Double Blind Trial Randomized Trial
      • 5.2.1.1.2 Single Blind Trial Randomized Trial
      • 5.2.1.1.3 Non-blind Randomized Trial
      • 5.2.1.2 Adaptive Clinical Trial
      • 5.2.1.3 Non-randomized Control Trial
    • 5.2.2 Observational Studies
      • 5.2.2.1 Cohort Study
      • 5.2.2.2 Case Control Study
      • 5.2.2.3 Cross Sectional Study
      • 5.2.2.4 Ecological Study
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clinipace
    • 6.1.2 Eli Lilly and Company
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 ICON PLC
    • 6.1.5 IQVIA
    • 6.1.6 Laboratory Corporation of America
    • 6.1.7 Novo Nordisk AS
    • 6.1.8 PAREXEL International Corporation
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Pharmaceutical Product Development LLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!